Axsome Therapeutics, Inc.

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 1579428

CEO Pay Ratio

23:1

Herriot Tabuteau, M.D.

CEO Total Comp

$33.8M

Herriot Tabuteau, M.D.

Median Employee

$437,980

Revenue

$638.5M

FY 2025

Net Income

-$183.2M

FY 2025

Free Cash Flow

-$93.9M

FY 2025

Net Margin

-28.7%

Insider Net (180d)

-$63.6M

0 buys / 16 sales

CEO Pay Accountability

CEO comp as % of net income

-18.45%

For every $1,000 of profit, $-184.54 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$638.5M	$385.7M	$270.6M	$50.0M	—
Gross Profit	—	—	—	—	—	—
Operating Income	-$166.8M	-$280.6M	-$231.8M	-$179.8M	-$124.7M
Net Income	-$183.2M	-$287.2M	-$239.2M	-$187.1M	-$130.4M
Operating CF	-$93.4M	-$128.4M	-$145.1M	-$116.5M	-$108.2M
Capex	$480.0K	$270.0K	$582.0K	$702.1K	$307.5K
Free Cash Flow	-$93.9M	-$128.7M	-$145.7M	-$117.2M	-$108.5M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	-26.1%	-72.7%	-85.7%	-359.3%	—
Net Margin	-28.7%	-74.5%	-88.4%	-374.0%	—
FCF Margin	-14.7%	-33.4%	-53.8%	-234.3%	—
R&D / Revenue	28.7%	48.5%	36.2%	115.8%	—
Effective Tax	0.3%	-0.0%	-0.4%	—	—
Debt / Equity	1.33	3.17	0.93	0.86	3.14
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Herriot Tabuteau, M.D.Chief Executive Officer and Chairman of the Board	—	—	—	—	—	$33.8M
Herriot TabuteauM.D.	$835.0K	$5.5M	$2.8M	$876.8K	$205.0K	$10.3M
Mark JacobsonM.A.	$575.0K	$2.1M	$1.1M	$388.0K	$95.6K	$4.2M
Nick PizzieC.P.A., M.B.A.	$530.0K	$1.8M	$933.3K	$358.0K	$86.6K	$3.7M
General Counsel	$505.0K	$766.5K	$1.5M	$398.0K	$42.7K	$3.2M
Hunter MurdockEsq.	$530.0K	$1.5M	$766.6K	$358.0K	$72.6K	$3.2M
Ari MaizelM.B.A.	$530.0K	$1.5M	$766.6K	$358.0K	$37.0K	$3.2M
Hunter Murdock, Esq.	—	—	—	—	—	—
Mark Jacobson, M.A.	—	—	—	—	—	—
Ari Maizel, M.B.A.	—	—	—	—	—	—
Nick Pizzie, C.P.A., M.B.A. · CFO	—	—	—	—	—	—